RecruitingPhase 3NCT06059144

Induced Hypertension in Acute PRogrESsive Perforating Artery Stroke Using Peripheral Dilute noREpinephrine


Sponsor

University Hospital, Bordeaux

Enrollment

358 participants

Start Date

Nov 28, 2024

Study Type

INTERVENTIONAL

Conditions

Summary

PRESSURE is a multicenter, prospective, randomized, open, blinded end-point assessed (PROBE) trial, that aims to evaluate the efficacy and safety of drug-induced hypertension using peripheral dilute norepinephrine, in patients with acute ischemic stroke in a perforating artery territory and experiencing early neurological deterioration.


Eligibility

Min Age: 18 Years

Plain Language Summary

Simplified for easier understanding

This trial is testing whether deliberately raising blood pressure using a diluted norepinephrine (adrenaline-like) drip can help stop a specific type of stroke from getting worse. This targets a stroke caused by a blockage in a small, deep brain artery. **You may be eligible if...** - You are 18 or older - You had a stroke in the last 72 hours affecting a small deep brain artery, confirmed on MRI - Your stroke symptoms have been noticeably worsening, and that worsening happened within the last 6 hours - Women of childbearing age must use effective contraception **You may NOT be eligible if...** - Your stroke was caused by a large artery or is a different type - You have very high blood pressure that cannot be safely elevated further - You have a history of bleeding in the brain Talk to your doctor to see if this trial is right for you.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

DRUGPeripheral intravenous norepinephrine

Norepinephrine (dilution: 10µg/ml, initial dose: 0.04µg/kg/min) will be titrated until MAP is between 110 and 120mmHG (with a maximal systolic blood pressure of 210mmHG) Gradually decrease of norepinephrine will start after 24h of NIHSS stabilization.


Locations(1)

CHU de Bordeaux

Bordeaux, France

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT06059144


Related Trials